Drug Evaluation Committee Results of a Fixed-point Survey of Patient and Public Involvement Activities in Drug Development by Pharmaceutical Companies
Clinical Evaluation Subcommittee
April 2026
This report summarizes the results of a fixed-point survey of pharmaceutical companies on Patient and Public Involvement/Engagement (PPI/E) activities (FY 2016, 2019, 2021, and 2024) conducted by the Clinical Evaluation Subcommittee. The survey shows the progress of pharmaceutical companies' PPI/E activities across 18 categories, including the introduction of PPI/E into their corporate philosophy and vision, development of internal systems, reflection of patient opinions in clinical trial planning and documentation, and sharing of trial results with patients.
While PPI/E activities have made steady progress over the past eight years, there are still some issues such as lack of internal systems, lack of know-how, lack of operational efficiency, and lack of awareness. While PPI/E activities have made steady progress over the past eight years, issues such as a lack of internal organization and know-how, and low priority given to PPI/E activities in business operations have also become apparent.
We hope that this report will be of help for collaboration among industry, government, and academia, as it provides a bird's-eye view of the achievements and challenges in promoting PPI/E activities in the future.
Japan Pharmaceutical Manufacturers Association Drug Evaluation Committee
Clinical Evaluation Subcommittee Ongoing Issues Team 5